Table 3.
Treatment and outcomes among children with GBS
| 2019 (33 cases) | 2020 (10 cases) | P | |
|---|---|---|---|
| Treatment modality | IVIg-32 (96.9) Steroids-1 (3.1) |
IVIg-10 (100) | 0.578 |
| No of days on ventilator | 15 (10-53) | None | - |
| GBS Disability Score (At discharge) | 3 (3.5-5.0) N=29 |
2 (1-3) N=8 |
0.071 |
| Clinical diagnosis at discharge | Sensorimotor-11 (33.3) | Sensorimotor-4 (40) | 0.220 |
| Pure motor-16 (48.5) | Pure motor-3 (30) | ||
| MFS-0MFS-GBS overlap-1 (3.1) | MFS-1 (10) | ||
| Missing-5 (15.1) | Missing-2 (20) | ||
| mRS At discharge | 3 (2-4) | 1 (1-3.5) | 0.042 |
| N=31 | N=9 | ||
| Complications | VAP-7 (21.2) | None-8 (80) | 0.920 |
| DVT-1 (3.1) | Missing-2 (20) | ||
| None-25 (75.7) | |||
| GBS profile | Monophasic-10 (100%) | Monophasic-10 (100%) | - |
| GBS Disability Score at 3 months post-discharge | 2 (0-3) | 0 | 0.009 |
| N=24 | N=8 | ||
| In-Hospital Mortality | None | None | - |
| Ventilator Dependency | Yes-2 (6.1) No-31 (93.9) |
None | - |
Values represented as median (interquartile range); GBS = Guillain Barre syndrome; MFS = Miller Fisher syndrome; mRS = Modified Rankin Scale; DVT= Deep vein thrombosis; VAP= Ventilator associated pneumonia